Apollomics Ends Phase 3 Uproleselan Trial in Acute Myeloid Leukemia; Shares Fall

MT Newswires Live2024-12-20

Apollomics (APLM) shares were down more than 13% in recent Friday trading after the company said it will terminate its phase 3 study in relapsed or refractory acute myeloid leukemia, which "did not demonstrate favorable benefit for uproleselan."

Chief Executive Guo-Liang Yu said the results were expected because a global phase 3 trial conducted by its partner Glycomimetics in a similar patient group earlier this year failed to meet its primary goal.

"Our regulatory and commercial strategy in China has always required a positive global phase 3 trial, and therefore we are currently wrapping up this program," Apollomics Chief Executive Guo-Liang Yu said.

The company said it expects future uproleselan program costs to be under $500,000.

Price: 8.15, Change: -1.25, Percent Change: -13.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492474804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492474804","market":"us","top_or_hot":-1,"title":"Apollomics Ends Phase 3 Uproleselan Trial in Acute Myeloid Leukemia; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/APLMW\">Apollomics</a> (APLM) shares were down more than 13% in recent Friday trading after the company said it will terminate its phase 3 study in relapsed or refractory acute myeloid leukemia, which \"did not demonstrate favorable benefit for uproleselan.\"</p><p>Chief Executive Guo-Liang Yu said the results were expected because a global phase 3 trial conducted by its partner Glycomimetics in a similar patient group earlier this year failed to meet its primary goal.</p><p>\"Our regulatory and commercial strategy in China has always required a positive global phase 3 trial, and therefore we are currently wrapping up this program,\" Apollomics Chief Executive Guo-Liang Yu said.</p><p>The company said it expects future uproleselan program costs to be under $500,000.</p><p>Price: 8.15, Change: -1.25, Percent Change: -13.30</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apollomics Ends Phase 3 Uproleselan Trial in Acute Myeloid Leukemia; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApollomics Ends Phase 3 Uproleselan Trial in Acute Myeloid Leukemia; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apollomics (APLM) shares were down more than 13% in recent Friday trading after the company said it will terminate its phase 3 study in relapsed or refractory acute myeloid leukemia, which \"did not ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLMW","symbol_name":"Apollomics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492474804","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492474804","pubTimestamp":1734708007,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Apollomics  shares were down more than 13% in recent Friday trading after the company said it will terminate its phase 3 study in relapsed or refractory acute myeloid leukemia, which \"did not demonstrate favorable benefit for uproleselan.\"Chief Executive Guo-Liang Yu said the results were expected because a global phase 3 trial conducted by its partner Glycomimetics in a similar patient group earlier this year failed to meet its primary goal.\"Our regulatory and commercial strategy in China has always required a positive global phase 3 trial, and therefore we are currently wrapping up this program,\" Apollomics Chief Executive Guo-Liang Yu said.The company said it expects future uproleselan program costs to be under $500,000.Price: 8.15, Change: -1.25, Percent Change: -13.30","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLMW":"Apollomics","BK4139":"生物科技","APLM":"Apollomics Inc"},"translate_title":"Apollomics结束急性髓系白血病3期Uproleselan试验；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLMW":1,"APLM":0.9},"content_text":"Apollomics (APLM) shares were down more than 13% in recent Friday trading after the company said it will terminate its phase 3 study in relapsed or refractory acute myeloid leukemia, which \"did not demonstrate favorable benefit for uproleselan.\"Chief Executive Guo-Liang Yu said the results were expected because a global phase 3 trial conducted by its partner Glycomimetics in a similar patient group earlier this year failed to meet its primary goal.\"Our regulatory and commercial strategy in China has always required a positive global phase 3 trial, and therefore we are currently wrapping up this program,\" Apollomics Chief Executive Guo-Liang Yu said.The company said it expects future uproleselan program costs to be under $500,000.Price: 8.15, Change: -1.25, Percent Change: -13.30","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492474804"}